김태환 교수 연구실
article|
green
·인용수 269
·2024
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Thomas Powles, James W.F. Catto, Matthew D. Galsky, Hikmat Al‐Ahmadie, Joshua J. Meeks, Hiroyuki Nishiyama, Toan Quang Vu, Lorenzo Antonuzzo, Paweł Wiechno, Vagif Atduev, Ariel Galapo Kann, Tae‐Hwan Kim, Cristina Suárez, Chao-Hsiang Chang, Florian Roghmann, Mustafa Özgüroğlu, Bernhard J. Eigl, Niara Oliveira, Tomáš Büchler, Moran Gadot, Yousef Zakharia, J. Armstrong, Ashok Kumar Gupta, Stephan Hois, Michiel S. van der Heijden
IF 78.5New England Journal of Medicine
초록
Perioperative durvalumab plus neoadjuvant chemotherapy led to significant improvements in event-free survival and overall survival as compared with neoadjuvant chemotherapy alone. (Funded by AstraZeneca; NIAGARA ClinicalTrials.gov number, NCT03732677; EudraCT number, 2018-001811-59.).
키워드
DurvalumabMedicinePerioperativeChemotherapyBladder cancerNeoadjuvant therapyCancerLaryngectomyOncologyUrology